Sigurd Vitols
Overview
Explore the profile of Sigurd Vitols including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berg J, Kallen K, Andolf E, Hellstrom-Westas L, Ekeus C, Alvan J, et al.
Value Health
. 2022 Nov;
26(5):639-648.
PMID: 36396536
Objectives: There is a lack of consensus around the definition of delivery by cesarean section (CS) on maternal request, and clinical practice varies across and within countries. Previous economic evaluations...
2.
Sundvall H, Vitols S, Wallerstedt S, Fastbom J
Eur J Clin Pharmacol
. 2022 Jul;
78(9):1459-1467.
PMID: 35788725
Purpose: To investigate the prevalence and initiation of statins as well as treatment intensity in the oldest old, with younger olds as a reference. Methods: A population-based cohort was used,...
3.
Sundvall H, Fastbom J, Wallerstedt S, Vitols S
Eur J Clin Pharmacol
. 2019 Mar;
75(7):959-967.
PMID: 30826850
Purpose: To investigate statin use in the elderly by age (≥ 80 vs. 65-79 years) in relation to established indications. Methods: A population-based cohort, including data from four registers, encompassing...
4.
Bhuiyan H, Masquelier M, Tatidis L, Gruber A, Paul C, Vitols S
Lipids
. 2017 May;
52(6):523-534.
PMID: 28488049
Leukemic cells isolated from most patients with acute myelogenous leukemia (AML) have higher low density lipoprotein (LDL) uptake than normal mononuclear blood cells. Little is known, however, about the mechanism...
5.
Welch V, Akl E, Guyatt G, Pottie K, Eslava-Schmalbach J, Ansari M, et al.
J Clin Epidemiol
. 2017 Apr;
90:59-67.
PMID: 28412464
Objectives: This article introduces the rationale and methods for explicitly considering health equity in the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology for development of clinical, public health,...
6.
Welch V, Akl E, Pottie K, Ansari M, Briel M, Christensen R, et al.
J Clin Epidemiol
. 2017 Apr;
90:76-83.
PMID: 28389397
Objectives: The aim of this paper is to describe a conceptual framework for how to consider health equity in the Grading Recommendations Assessment and Development Evidence (GRADE) guideline development process....
7.
Wallerstedt S, Fastbom J, Linke J, Vitols S
Pharmacoepidemiol Drug Saf
. 2016 Nov;
26(1):9-16.
PMID: 27859947
Purpose: To analyse the prevalence of long-term use of proton pump inhibitors (PPI) with respect to underlying diseases and drugs, and to find predictors for such treatment when an evident...
8.
Heibert Arnlind M, Fryklund L, Vitols S, Bertilsson G
Eur J Clin Pharmacol
. 2016 Jul;
72(10):1161-1169.
PMID: 27444173
Purpose: We systematically reviewed published observational studies and randomized controlled trials (RCT) reports of clinical trials on erythropoiesis-stimulating agents (ESA's). Only studies evaluating the risk of developing anti-drug antibodies (ADA)...
9.
Ryden L, Heibert Arnlind M, Vitols S, Hoistad M, Ahlgren J
Breast
. 2016 Mar;
26:106-14.
PMID: 27017249
Tamoxifen (TAM) and aromatase inhibitors (AI) are adjuvant therapy options for postmenopausal women with estrogen receptor positive (ER+) breast cancer. This systematic review of seven randomized controlled studies comparing TAM...
10.
Fotoohi A, Karim H, Lafolie P, Pohanka A, Ostervall J, Hatschek T, et al.
Ther Drug Monit
. 2015 Oct;
38(2):239-45.
PMID: 26485084
Background: Tamoxifen is still an important antihormonal treatment option for patients with breast cancer and estrogen receptor-positive tumors. More than 20% of patients relapse despite treatment. The drug is usually...